Last reviewed · How we verify
Streptococcal infection of skin — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Orbactiv | ORITAVANCIN | Melinta Therap | Lipoglycopeptide Antibacterial | 2014-01-01 | ||
| Orbactiv | Orbactiv | Melinta Therapeutics, LLC |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Melinta Therap · 1 drug in Streptococcal infection of skin
- Melinta Therapeutics, LLC · 1 drug in Streptococcal infection of skin
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Streptococcal infection of skin:
- Streptococcal infection of skin treatment updates — RSS
- Streptococcal infection of skin treatment updates — Atom
- Streptococcal infection of skin treatment updates — JSON
Cite this brief
Drug Landscape (2026). Streptococcal infection of skin — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/streptococcal-infection-of-skin. Accessed 2026-06-10.
Related
- Streptococcal infection of skin full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing